Search Bar & Filters
Found 75 Actively Recruiting clinical trials
Actively Recruiting
This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating how CDR132L, a potential new medicine, affects the structure and function of the heart in people living with heart failure. The study focuses on individuals with preserved ejection fraction and left ventricular hypertrophy. It is a phase 2, randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of CDR132L on reversing cardiac remodeling. Participants will be randomly assigned to receive one of three different doses of CDR132L or a placebo. All treatments are given as intravenous infusions once every 4 weeks for 48 weeks. Throughout the study, participants will continue their individually tailored guideline-directed standard care therapy for heart failure. The trial duration is about 60 weeks. During the study, participants will undergo various assessments, including measuring changes in microRNA-132 levels as the primary outcome at 24 weeks. Secondary outcomes include changes in heart structure measured by cardiac magnetic resonance imaging and blood biomarkers, as well as monitoring adverse events up to 60 weeks. Participants will receive regular infusions and attend scheduled visits for monitoring and safety evaluations.
Actively Recruiting
Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.
1-10 of 75
1